Trial Profile

A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary) ; Bevacizumab; Carmustine; Lomustine; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Acronyms KING
Sponsors Karyopharm Therapeutics

Most Recent Events

31 Aug 2023 Protocol has been amended as above-1) treatment arms has been changed from 10 to 8. 2)Recruitment status has been terminated. 3) actual number of patients has been changed to 74
31 Aug 2023 Status changed from active, no longer recruiting to discontinued.
11 Jul 2023 Planned End Date changed from 1 Apr 2024 to 1 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com